Kistefos

Kistefos, established in 1989, is a Norwegian investment firm that specializes in both fund of funds and direct investments. For direct investments, the company focuses on early stage, growth capital, and buyouts, with a minimum investment of NOK 10 million ($1.85 million). It operates across various sectors, including offshore, shipping, financial services, real estate, information technology, and telecommunication. Kistefos seeks significant ownership stakes, aiming to be an active partner to management teams and founders, and typically exits investments within three to seven years.

Espen Franzon Amundsen

Investment Analyst

Nishant Fafalia

Investment Manager

Ola Beinnes Fosse

CFO

Hege Galtung

Managing Director, AS Holding

Tom Holberg

Investment Director

Gunnar Jacobsen

Investment Director

Nicolai Lunde

Investment Analyst

Otto Moltke-Hansen

Investment Analyst

Bengt Rem

CEO

Bengt A Rem

CEO

Lars Petter Utseth

Investment Manager

Past deals in Oslo

Kappa Bioscience

Venture Round in 2009
Kappa Bioscience AS, established in 2006 and headquartered in Oslo, Norway, specializes in the development and production of vitamin K2 as menaquinone-7. The company pioneers the synthesis of MK-7, offering it under the brand name K2VITAL to food supplement and fortified food manufacturers worldwide through its global sales division Kappa Ingredients GmbH and a network of distributors. Kappa Bioscience's product portfolio includes microencapsulated DELTA for stability in mineral formulations, along with other vitamin K2 variants like MK-7 for food supplements and fortified foods. The company's innovations ensure high ingredient purity, scalability, and secure supply chains, enabling broader market access for its clients.

Promon

Venture Round in 2008
Promon AS is a cybersecurity company based in Oslo, Norway, that specializes in developing and selling security software for businesses that handle sensitive information. Founded in 2006, Promon provides a suite of application security solutions designed to protect online services and software applications from security threats. Its products are aimed at online service providers, covering areas such as online banking, e-commerce, and enterprise resource planning systems. Promon's security technology extends beyond the application itself, proactively detecting and blocking potential threats to prevent data tampering and leakage. Through its integrated service protection and application protection offerings, Promon ensures the integrity and confidentiality of sensitive information for its clients.

OstomyCure

Venture Round in 2007
OstomyCure AS is a Medical Technology company with a headquarter in Oslo, Norway. The company develops a revolutionary technology called Transcutaneous Implant Evacuation System, The TIES® System. The TIES® Continent Ileostomy System, is a titanium implant solution with a lid intended to replace a conventional ileostomy. It allows a more carefree life for patients who suffer from inflammatory bowel diseases such as Crohn´s disease, Ulcerative colitis, multiple cancer or other related diseases that need the removal of the colon (large intestine). The TIES® System is the result of several years of research combined with the latest 3D manufacturing technology, developed and produced in accordance with regulatory standards to ensure safety for the patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.